Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector

• Published in: Cancer research (Chicago, Ill.) Vol. 66; no. 5; pp. 2509 - 2513
• Main Authors: MCKEE, Trevor D, GRANDI, Paola, MOK, Wilson, ALEXANDRAKIS, George, INSIN, Numpon, ZIMMER, John P, BAWENDI, Moungi G, BOUCHER, Yves, BREAKEFIELD, Xandra O, JAIN, Rakesh K
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.03.2006
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Collagenases - metabolism; Collagenases - pharmacology; Dermatology; Fibrillar Collagens - metabolism; Gene Expression; Genetic Vectors - pharmacokinetics; Green Fluorescent Proteins - biosynthesis; Green Fluorescent Proteins - genetics; Herpes simplex virus; Herpesvirus 1, Human - genetics; Herpesvirus 1, Human - metabolism; Humans; Medical sciences; Melanoma - metabolism; Melanoma - therapy; Melanoma - virology; Mice; Mice, SCID; Oncolytic Virotherapy - methods; Pharmacology. Drug treatments; Tissue Distribution; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; Virion - metabolism; Xenograft Model Antitumor Assays; Human; Herpesviridae; Alphaherpesvirinae; Glycoprotein; Transplantation; Malignant tumor; Oncolytic virus; Heterograft; Heterotransplantation; Virus; Degradation; Treatment; Efficiency; Surgery; Animal; Collagen; Malignant melanoma; Graft; Herpesvirus hominis; Vector
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-05-2242

Oncolytic viral therapy provides a promising approach to treat certain human malignancies. These vectors improve on replication-deficient vectors by increasing the viral load within tumors through preferential viral replication within tumor cells. However, the inability to efficiently propagate throughout the entire tumor and infect cells distant from the injection site has limited the capacity of oncolytic viruses to achieve consistent therapeutic responses. Here we show that the spread of the oncolytic herpes simplex virus (HSV) vector MGH2 within the human melanoma Mu89 is limited by the fibrillar collagen in the extracellular matrix. This limitation seems to be size specific as nanoparticles of equivalent size to the virus distribute within tumors to the same extent whereas smaller particles distribute more widely. Due to limited viral penetration, tumor cells in inaccessible regions continue to grow, remaining out of the range of viral infection, and tumor eradication cannot be achieved. Matrix modification with bacterial collagenase coinjection results in a significant improvement in the initial range of viral distribution within the tumor. This results in an extended range of infected tumor cells and improved virus propagation, ultimately leading to enhanced therapeutic outcome. Thus, fibrillar collagen can be a formidable barrier to viral distribution and matrix-modifying treatments can significantly enhance the therapeutic response.